American Association for Cancer Research
00085472can121377-sup-f3_131k.pdf (131.37 kB)

Supplementary Figure 3 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases

Download (131.37 kB)
journal contribution
posted on 2023-03-30, 21:35 authored by Arcadi Cipponi, Marjorie Mercier, Teofila Seremet, Jean-François Baurain, Ivan Théate, Joost van den Oord, Marguerite Stas, Thierry Boon, Pierre G. Coulie, Nicolas van Baren

PDF file - 131K, Procedure for the preparation of immunoglobulin VDJC1 libraries



Lymphoid neogenesis, or the development of lymphoid structures in nonlymphoid organs, is frequently observed in chronically inflamed tissues, during the course of autoimmune, infectious, and chronic graft rejection diseases, in which a sustained lymphocyte activation occurs in the presence of persistent antigenic stimuli. The presence of such ectopic lymphoid structures has also been reported in primary lung, breast, and germline cancers, but not yet in melanoma. In this study, we observed ectopic lymphoid structures, defined as lymphoid follicles comprising clusters of B lymphocytes and follicular dendritic cells (DC), associated with high endothelial venules (HEV) and clusters of T cells and mature DCs, in 7 of 29 cutaneous metastases from melanoma patients. Some follicles contained germinal centers. In contrast to metastatic lesions, primary melanomas did not host follicles, but many contained HEVs, suggesting an incomplete lymphoid neogenesis. Analysis of the repertoire of rearranged immunoglobulin genes in the B cells of microdissected follicles revealed clonal amplification, somatic mutation and isotype switching, indicating a local antigen-driven B-cell response. Surprisingly, IgA responses were observed despite the nonmucosal location of the follicles. Taken together, our findings show the existence of lymphoid neogenesis in melanoma and suggest that the presence of functional ectopic lymphoid structures in direct contact with the tumor makes the local development of antimelanoma B- and T-cell responses possible. Cancer Res; 72(16); 3997–4007. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager